Penumbra (PEN) Free Cash Flow Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 9.73% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -109.40% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 133.09% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 363.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 108.16% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 29.12% |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | 106.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106.46% |
| Dec 31, 2025 | 27.24% |
| Sep 30, 2025 | 68.11% |
| Jun 30, 2025 | 62.47% |
| Mar 31, 2025 | 9.34% |
| Dec 31, 2024 | 39.40% |
| Sep 30, 2024 | 145.93% |
| Jun 30, 2024 | -7.43% |
| Mar 31, 2024 | 251.61% |
| Dec 31, 2023 | 2,196.49% |
| Sep 30, 2023 | 207.72% |
| Jun 30, 2023 | 144.37% |
| Mar 31, 2023 | 197.51% |
| Dec 31, 2022 | 91.31% |
| Sep 30, 2022 | -156.89% |
| Jun 30, 2022 | -1,208.92% |
| Mar 31, 2022 | 42.78% |
| Dec 31, 2021 | -1,198.07% |
| Sep 30, 2021 | 187.25% |
| Jun 30, 2021 | 88.17% |
| Mar 31, 2021 | -3.12% |
| Dec 31, 2020 | -141.20% |
| Sep 30, 2020 | -42.28% |
| Jun 30, 2020 | -2,028.58% |
| Mar 31, 2020 | -448.19% |
| Dec 31, 2019 | -39.16% |
| Sep 30, 2019 | 100.28% |
| Jun 30, 2019 | 356.17% |
| Mar 31, 2019 | -128.48% |
| Dec 31, 2018 | 218.66% |
| Sep 30, 2018 | 9.45% |
| Jun 30, 2018 | 62.17% |
| Mar 31, 2018 | 1,128.10% |
| Dec 31, 2017 | -40.52% |
| Sep 30, 2017 | 296.47% |
| Jun 30, 2017 | 82.50% |
| Mar 31, 2017 | 68.64% |
| Dec 31, 2016 | 67.64% |
| Sep 30, 2016 | 185.11% |
| Jun 30, 2016 | -58.92% |
| Mar 31, 2016 | 4.72% |
| Dec 31, 2015 | -58.59% |